Ligo Biosciences
Cambridge, United States· Est.
A private synthetic‑biology platform building AI‑designed protein therapeutics for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $150M
AI Company Overview
A private synthetic‑biology platform building AI‑designed protein therapeutics for oncology and immunology.
OncologyImmunologyRare Diseases
Technology Platform
Ligo’s AI‑driven de novo protein design platform computationally engineers novel biologics with precise functional and pharmacokinetic properties, enabling rapid creation of bispecifics, cytokine mimetics, and other therapeutic scaffolds.
Opportunities
Ligo can leverage its platform to address unmet targets in oncology and immunology, expand into rare‑disease therapeutics, and monetize through partnerships or licensing.
Risk Factors
Technical challenges in de novo protein validation, regulatory hurdles, and competition from established biologics developers could impede progress.
Competitive Landscape
Competitors include traditional biologics firms and synthetic‑biology startups; Ligo differentiates through its AI‑centric design engine and focus on rapid, scalable protein engineering.